Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Gillian Barre Syndrome; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced guillain barre syndrome (Verbatim: Gillian Barre Syndrome) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was not reported. It was unknown if the reporter considered the guillain barre syndrome to be related to Shingles vaccine. The company considered the guillain barre syndrome to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 23-JAN-2026 This case was reported by a patient via interactive digital media. Patient suggested to do research for Guillain Barre Syndrome because it was a possible side effect of the shots. It paralyzed him/her for four months, and even three years later he/she still had so much nerve damage that he/she did not have good use of his/her legs. It was nothing to fool around with, it could kill someone in half an hour. Patient knew this firsthand, because it nearly did four or five times before doctors were able to get his/her lungs working again. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Guillain-Barre syndrome (not meeting BC Criteria), an unknown time after receiving Shingles vaccine, in a patient. Based on the available information a possible causality that the event was caused by the GSK products cannot be ascertained. Consent for further follow up has not been received.